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Abstract - Tracer-kinetic analysis of dynamic contrast-enhanced magnetic resonance imaging data
is commonly performed with the well-known Tofts model and nonlinear least squares (NLLS) regres-
sion. This approach yields point estimates of model parameters, uncertainty of these estimates can
be assessed e.g. by an additional bootstrapping analysis. Here, we present a Bayesian probabilistic
modeling approach for tracer-kinetic analysis with a Tofts model, which yields posterior probability
distributions of perfusion parameters and therefore promises a robust and information-enriched alter-
native based on a framework of probability distributions. In this manuscript, we use the Quantitative
Imaging Biomarkers Alliance (QIBA) Tofts phantom to evaluate the Bayesian Tofts Model (BTM)
against a bootstrapped NLLS approach. Furthermore, we demonstrate how Bayesian posterior proba-
bility distributions can be employed to assess treatment response in a breast cancer DCE-MRI dataset
using Cohen’s d. Accuracy and precision of the BTM posterior distributions were validated and found
to be in good agreement with the NLLS approaches, and assessment of therapy response with respect
to uncertainty in parameter estimates was found to be excellent. In conclusion, the Bayesian model-
ing approach provides an elegant means to determine uncertainty via posterior distributions within a
single step and provides honest information about changes in parameter estimates.
Keywords - Bayesian inference, tracer-kinetic modeling, DCE-MRI, perfusion
1 Introduction
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a noninvasive imaging technique
used to quantify microvascular tissue perfusion with the help of a contrast agent (CA) (Ingrisch and Sour-
bron, 2013). In MRI, a gadolinium-based CA is used most commonly and injected intravenously after the
acquisition of pre-contrast baseline scans. The CA increases T1 and T2 relaxation rates of surrounding water
protons and causes signal enhancement in a T1-weighted acquisition. By measuring multiple T1-weighted im-
ages during the passage of the CA through the tissue of interest, a time-dependent CA concentration can be
extracted from the signal-time course of each voxel. Besides determining semi-quantitative and descriptive
parameters from the concentration curves, e.g. time to peak, area under curve, or maximum, quantita-
tive perfusion parameters can be obtained by fitting pharmacokinetic (PK) models to the data (Sourbron
and Buckley, 2012, 2013; Roberts et al., 2006). Popular PK models that characterize CA transport from
DCE-MRI data are the classical Tofts model (TM) (Tofts, 1997), the extended Tofts model and the two
compartment exchange model (Sourbron and Buckley, 2011).
The standard approach for estimating PK parameters from DCE-MRI data is using non-linear regression
to determine a maximum likelihood estimator by non-linear least squares (NLLS) analysis (Seber and Wild,
2003). For this purpose, an optimizing algorithm aims to minimize the sum of squared residuals between
model and data and yields, if successful, a point estimate of model parameters. The NLLS approach is
widely used, and a number of software packages provide non-linear regression implementation of a range of
PK models (Huang et al., 2014a; Beuzit et al., 2016). Bayesian probabilistic modeling, on the other hand,
offers an alternative modeling approach within a framework of probability distributions. Briefly, a prior
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belief about model parameters is formulated as a probability distribution; this allows to incorporate domain
expertise, e.g. physical constraints. With dedicated algorithms, this prior belief is then updated with the
measured data and yields the posterior probability distributions of the parameters given the data (McElreath,
2015). Through recent algorithmic developments (Hoffman and Gelman, 2011) and the increasing availability
of computational power, the use of Bayesian modeling approaches is spreading in various disciplines and
has already shown to be a robust and accurate alternative for the analysis of MR imaging data (Schmid
et al., 2006; Orton et al., 2007; Woolrich et al., 2009; Dikaios et al., 2017; Tietze et al., 2018; Hansen
et al., 2019). The posterior probability distributions that result from Bayesian modeling greatly increase
the interpretability of analysis results. Compared to simple point estimates, entire parameter probability
distributions allow a straightforward assessment of, e.g., whether a parameter has truly changed in the course
of a therapy, or whether the parameter change has only occurred within the uncertainty of the estimation
(Shukla-Dave et al., 2018).
In the present manuscript, we investigated Bayesian tracer-kinetic modeling in the context of DCE-MRI.
To this end, we implemented a Bayesian TM (BTM) with the purpose to i) evaluate accuracy against a
NLLS approach using a digital reference object, ii) validate uncertainty estimates against a bootstrapped
NLLS approach to assess the precision and iii) demonstrate how Bayesian posterior probability distributions
can be used to assess treatment response in a breast cancer DCE-MRI dataset.
2 Materials and Methods
2.1 Signal Conversion and Pharmacokinetic Models
In a typical DCE-MRI experiment, time-resolved signal intensity curves S(t) are extracted voxel-wise from
multiple T1-weighted images. To derive quantitative information, the measured signal intensities need to be
converted to CA concentration curves. For this purpose, the signal equation for the spoiled gradient echo
(SPGR) sequence in steady state can be used with the baseline signal S0(t), flip angle α, repetition time TR
and relaxation rate R1(t) as:
S(t) = S0 sin(α)
1− e−TRR1(t)
1− cos(α)e−TRR1(t) . (1)
One can solve Eq. (1) for the time-dependent relaxation rate R1(t):
R1(t) = − 1
TR
log
(
1−A
1− cos(α)A
)
, (2)
with the auxiliary variable
A = S(t)
S0
1− e−TRR10
1− cos(α)e−TRR10 . (3)
A time-dependent concentration can then be calculated from the linear relation to the change in relaxation
rates during and before administration of CA, R1(t) and R10, respectively:
c(t) = (R1(t)−R10)/r1, (4)
with the specific relaxivity of the gadolinium-based CA r1 (Pintaske et al., 2006).
A standard approach for the analysis of concentration-time curves in DCE-MRI data is the TM (Tofts and
Kermode, 1991; Tofts, 1997; Sourbron and Buckley, 2011) which assumes a negligible amount of intravascular
tracer and describes CA transportation as:
ct(t) = Ktranse−tkep ∗ cp(t). (5)
Here, ct(t) is the time-dependent concentrations of CA in the tissue of interest; cp(t) is the concentration
in the blood plasma of the tissue-feeding artery, often referred to as arterial input function (AIF). ct(t) and
cp(t) are connected with a convolution, expressed as “∗”. The parameter ve is the volume fraction of the
interstitium, the extravascular extracellular space (EES). Ktrans is defined as the transfer constant of CA
between blood plasma and EES. The rate constant kep = Ktrans/ve is the ratio of the transfer constant to
the EES (Tofts et al., 1999; Sourbron and Buckley, 2011).
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The tissue concentration ct(t) can be calculated from the measured signal S(t) with Eq. (1-4) using the
relaxation time T10 in tissue via R10 = 1/T10. Plasma concentration cp(t) in the AIF can be calculated
likewise using the relaxation time T10 of blood and the additional transformation from blood to plasma
concentration via the hematocrit hct:
cp(t) = cb(t) · (1− hct). (6)
The standard TM is used in the following within a classical NLLS likelihood framework and a Bayesian
framework to quantify perfusion in simulated and measured DCE-MRI data. To account for noise in any
observed data, an error term is added to the TM from Eq. (5) and an observation i is given as
yi = ct(ti, θ) + i. (7)
where the model parameters Ktrans and ve are summarized in the vector θ.
2.2 Data
2.2.1 Validation: QIBA DCE-MRI Phantom
To evaluate accuracy of estimates and compare results of different fitting approaches, a simulated phantom
with known PK parameters was investigated first. The Quantitative Imaging Biomarkers Alliance (QIBA)1
provides several freely available test images for DCE-MRI analysis, known as digital reference objects (DRO).
These have been used previously to validate various fitting algorithms and analysis toolkits (Ortun˜o et al.,
2013; Smith et al., 2015; Debus et al., 2019). The noise-free QIBA v6 Tofts version was chosen here. The
DRO contains simulated DCE-MRI data generated with the standard TM in Eq. (5) for a study duration of
t = 660 s with a temporal resolution ∆t = 0.5 s. Tissue concentration-time curves ct(t) have been created
for all combinations of Ktrans ∈ {0.01,0.02,0.05,0.1,0.2,0.35} min−1 and ve ∈ {0.01,0.05,0.1,0.2,0.5}, filling
a 10×10 pixel patch for each combination. Table 1 lists the parameters stated in the QIBA description2,
following QIBA’s DCE MRI quantification profile3 to convert signal intensities to concentrations (compare
Eq. (1-4)). For a more realistic setting, complex Gaussian noise with standard deviation σ = 0.2 relative to
the pre-contrast baseline signal S0 was added to the original noise-free test data. No noise was added to the
AIF for simplicity and to be able to reliably relate our results to published work of Smith et al. (2015) and
Ortun˜o et al. (2013). Fig. 1 shows a snapshot of the DRO signal intensities at t = 100s, the AIF and an
exemplary voxel with parameters Ktrans = 0.2 min−1 and ve = 0.2, respectively.
0.
01
0.
05 0.
1
0.
2
0.
5
ve
0.01
0.02
0.05
0.1
0.2
0.35
K
tr
an
s  (
m
in
1 )
(a) QIBA DRO v6
0 250 500
Time (s)
0
2500
5000
7500
10000
12500
Si
gn
al
 in
te
ns
ity
(b) AIF
0 250 500
Time (s)
500
1000
1500
2000
2500
Si
gn
al
 in
te
ns
ity
(c) Ktrans=0.2, ve=0.2
0
2500
5000
7500
10000
Figure 1: (a) Snapshot of the QIBA v6 Tofts DRO at t = 100 s; the AIF is the bottom strip of the image,
maximum of the AIF with timepoint labels in seconds are the top left strip and the zero patch (Ktrans = 0.0
min−1, ve = 0.5) is the top right strip. Intensity-time curves for AIF (b) and one pixel with Ktrans=0.2
min−1 and ve=0.2 with added noise (c), respectively.
1https://sites.duke.edu/dblab/qibacontent/
2https://sites.duke.edu/dblab/files/2015/05/Dynamic_v6_beta1_description_Rev1.pdf
3http://qibawiki.rsna.org/images/1/12/DCE-MRI_Quantification_Profile_v1.0.pdf
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2.2.2 Application: Breast Cancer DCE-MRI Data
The Quantitative Imaging Network (QIN) aims at improving quantitative imaging and does so by sharing
data which was acquired as part of various QIN studies, collected in The Cancer Imaging Archive (TCIA)4
(Clark et al., 2013). A set of breast cancer DCE-MRI data (Huang et al., 2014b) in DICOM format acquired
from 10 patients was used to demonstrate the performance of the BTM on clinical data. The dataset
contains DCE-MRI measurements acquired before (visit 1) and during (visit 2) preoperative neoadjuvant
chemotherapy (NACT), respectively. For three patients, pathologic complete response (pCR) was reported,
the remaining seven patients were classified as non-pCR. In addition, the dataset includes a region of interest
(ROI) per patient, drawn by an experienced breast radiologist. A sample-averaged AIF is provided as blood
concentration cb(t) and was converted to plasma concentration cp(t) using Eq. (6). Signal intensities within
the ROI were converted to tissue concentrations using Eq. (1-4). Parameters for the conversion are specified
in Table 1, further details can be found in the original work by Huang et al. (2014a).
Table 1: Parameters for the conversion from signal to concentration
T10(Tissue) T10(Blood) r1 α TR TE hct
QIBA DRO1 1000 ms 1440 ms 0.0045 Lmmol−1ms−1 30◦ 5 ms - 0.45
QIN Breast2 1666 ms3 1440 ms 0.0045 Lmmol−1ms−1 10◦ 6.2 ms 2.9 ms 0.45
1 Quantitative Imaging Biomarker Alliance Digital Reference Object QIBA v6 Tofts
2 Quantitative Imaging Network Breast Cancer Dataset
3 Personal communication with the author of Huang et al. (2014a)
2.3 Models and Analysis
2.3.1 Non-linear Least Squares Approach with Bootstrapping
The standard evaluation of DCE-MRI data is performed in a likelihood framework by fitting a non-linear
regression model to the concentration-time curve in every voxel. The NLLS approach minimizes the sum of
squared errors between measured data yi at timepoint ti for i = 0, 1, ..., N and the model function ct(ti) in
Eq. (7)
min
N∑
i=0
(yi − ct(ti, θ))2 = min
N∑
i=0
2i (8)
to infer the best guess parameter θˆ. Assuming normally distributed noise i, the least-squares estimator θˆ
equals the maximum-likelihood estimator (Seber and Wild, 2003).
An implementation of the Broyden-Fletcher-Goldberg-Shano (L-BFGS) algorithm (Byrd et al., 1994; Zhu
et al., 1997) in SciPy5 (Jones et al., 2001) was used for inference of the parameters via the optimize.minimize
function. Initial values for Ktrans and ve were set to 0.001. The concentration curves of the DRO were then
fitted and parameter maps were constructed for Ktrans and ve. By comparing them to the true parameter
maps, percentage error maps were calculated as θ%err = (θˆ − θtrue)/θtrue.
A bootstrap method was implemented to assess the uncertainty of θˆ (Kershaw and Buckley, 2006). For
that, the residuals, i.e. the difference between the fitted and the measured curve were calculated. In a
next step, the residuals were resampled by randomly drawing samples with replacement. Subsequently,
the resampled residuals were added to the fitted curve and the TM was used to determine another set of
estimates, equivalent to inferring the original best guess. The number of iterations was set to 1000.
Uncertainty maps were then calculated from the bootstrap samples for the NLLS approach. Denoted as
σ, half the width between 17th and 83rd percentile was considered a more robust measure for the precision
than the standard deviation and is used throughout this work. For samples following a Gaussian normal
distribution, σ would be equal to the standard deviation.
4https://wiki.cancerimagingarchive.net/display/Public/Collections
5Python 3.6.6, scipy 1.1.0, https://www.scipy.org/
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2.3.2 Bayesian Inference and Implementation
The alternative evaluation is performed in a Bayesian framework which infers a full posterior distribution
P (θ | y) of the model parameters θ given an observation of data y. The observational error i for each
measurement yi at timepoint ti for i = 0, 1, ..., N in Eq. (7) is assumed to be Gaussian with standard
deviation σ. Hence, the joint observations of CA concentration in each voxel, conditional on the parameters,
are modeled in the likelihood as
P (y | θ) =
N∏
i=0
N (yi | ct(ti, θ), σ2), (9)
with N representing a normal distribution and ct(ti, θ) the CA tissue concentration evaluated with the TM
in Eq. (5).
Information about the parameters prior to the observation of data are specified in the prior distribution
P (θ), enforcing physical or biological constraints. The likelihood of the data P (y | θ) and the product of the
prior probability densities P (θ) are combined with the observed data to infer the joint posterior distribution
via Bayes’ theorem:
P (θ | y) = P (y | θ)P (θ)
P (y) . (10)
The denominator in Eq. (10) is referred to as model evidence and calculates as P (y) =
∫
P (θ)P (y | θ)dθ.
If the complexity of the model allows no analytical solution to this integral, Markov Chain Monte Carlo
(MCMC) methods (Gilks et al., 1995) offer a means to determine the posterior probability distribution.
Briefly, a MCMC algorithm draws samples from a target distribution, which equals the desired posterior
distribution. The accepted parameter proposals are stored in a chain or trace of estimates (Kruschke, 2014).
The BTM was implemented in Stan (Carpenter et al., 2017), an open-source software package, using
pystan6. In the present analysis, weakly informative priors were chosen. In particular, for the volume
fraction ve ∈ [0, 1] a beta prior ve ∼ Beta(α = 2, β = 2) was chosen and for Ktrans ∈ R+ a gamma prior
was specified Ktrans(min−1) ∼ Gamma(α = 1.1, β = 1/0.002). The prior for the standard deviation of the
observational error was set to σ(mmol/L) ∼ LogNormal(µ = 0, σ = 1). The appendix A provides a prior
predictive check on these prior distributions. MCMC samples were drawn from the posterior distribution
with the No-U-Turn (NUTS) algorithm (Hoffman and Gelman, 2011). The number of iterations was set to
1000, sampled in two chains simultaneously, following a warm-up period of 500 iterations. Stan also reports
divergences of the sampling algorithm and indicates the need to update the default settings of NUTS, e.g.
initial step size and target acceptance rate.
To monitor the convergence of the MCMC chains to the target distribution, different diagnostics are
automatically run alongside in Stan. The potential scale reduction statistic, Rˆ, by Gelman and Rubin
(1992) compares the sample variance within and across chains, and indicates if chains have not converged
to a common distribution (Rˆ > 1.1). The effective sample size Neff indicates the degree of uncertainty in
estimates due to autocorrelation of samples (Geyer, 2011).
All concentration curves of the DRO were then fitted with the BTM to obtain posterior probability
distributions of the parameters θ. To be able to compare the distributions to point estimates and to generate
parameter maps, two hallmarks of the posterior distributions were determined: the median and, as for the
bootstrap samples, half the distance between the 17th and 83rd percentile, denoted as σ. By comparing the
median parameter maps to the true parameter maps, a map of the percentage error was calculated as above
to assess the accuracy of estimates.
To evaluate the breast cancer DCE-MRI datasets, the mean tissue concentration curve over the ROI
ct,ROI(t) was calculated for each patient and both visits. Subsequently, all concentration-time curves were
fitted with the BTM to infer posterior distributions for the model parameters θ. To ensure that the model
adequately captured the underlying data generating process, a posterior predictive check (PPC) was per-
formed. Briefly, we used the BTM to generate new predictive data yˆ and checked if it resembled the observed
data. The full posterior distribution is exploited in this way to generate a posterior predictive distribution
P (yˆ|y) =
∫
P (yˆ|θ)P (θ|y)dθ, (11)
6Python 3.6.6, pystan 2.18.0, https://pystan.readthedocs.io/
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which propagates the uncertainty in the parameter estimates to uncertainty about prediction (Betancourt,
2015; McElreath, 2015; Gabry et al., 2017). In this way, PPCs allow to detect systematic modeling errors
and violations of model assumptions. Subsequently, the posterior distributions of Ktrans were compared
across visits for all patients with the objective to discriminate between patients with pCR and non-pCR.
2.4 Statistical Analysis
A quantitative statistical measure for signal fidelity is the structural similarity index (SSIM) (Wang et al.,
2004). It gives an average value over similarities of three key elements of an image: luminance, contrast
and structure (Zhou Wang and Bovik, 2009). To assess the accuracy of parameter estimates for the DRO,
the SSIM was calculated between the estimated and the true parameter maps. As a comparison, the root-
mean-squared error (RMSE) was calculated alongside. In order to get reasonable values for RMSE, outliers
in Ktrans-estimates obtained from NLLS fitting needed to be restricted to one. In addition, the SSIM was
calculated between the σ-uncertainty maps determined with the BTM and the bootstrapping method to
assess similarities in the precision of estimates.
To compare the Ktrans posterior distributions between visits for the breast cancer DCE-MRI dataset,
Cohen’s d was calculated for each of the ten patients as:
d = x¯1 − x¯2√
(σ21 + σ22)/2
. (12)
x¯ represents the average Ktrans value per visit, σ its standard deviation. In this way, the width of the
posterior distributions are incorporated into a single value. Compared to just reporting the percentage
change of Ktrans mean values, the uncertainty in parameter estimation is accounted for. An univariate
logistic regression (ULR) model, implemented in scikit-learn7 (Pedregosa et al., 2011), was fitted to the
Cohen’s d values. The receiver operating characteristic (ROC) area under curve (AUC) was calculated in
order to obtain a quantitative measure for the assessment of response.
3 Results
3.1 Validation: QIBA DCE-MRI Phantom
Concentration-time curves of the DRO were evaluated within a Bayesian and likelihood framework. The
resulting parameter estimates for Ktrans are exemplarily shown in Fig. 2 for the Bayesian approach (a)
and the NLLS reference (d). Note that the voxels in the Bayesian framework show median values of their
respective posterior distributions while voxels in the likelihood framework represent point estimates. In
general, the parameter maps show high accordance with the true values. The corresponding percentage
error maps in the middle column (b) and (e) display relatively low errors for all regions with ve > 0.01 for
both methods. Low accuracy, hence high percentage errors are observed for regions where ve = 0.01. SSIM
between estimated and true Ktrans-maps is higher for the BTM than for the NLLS approach. Furthermore,
RMSE is lower for the BTM for both PK parameter maps. Details are provided in Table 2.
Table 2: SSIM and RMSE between estimated DRO Ktrans and ve parameter
maps and ground truth for both approaches; SSIM of 100% indicates perfect
similarity.
Ktrans ve
BTM NLLS BTM NLLS
SSIM 96 % 91 % 92 % 94 %
RMSE 2.5 % 7.0 % 4.1 % 5.4 %
BTM = Bayesian Tofts model; NLLS = Non-linear least squares approach; SSIM =
Structural similarity index; RMSE = Root-mean-squared error
7Python 3.6.6, scikit-learn 0.20.0, https://scikit-learn.org/
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The right column of Fig. 2 displays the precision of the parameter estimates evaluated with the BTM (c)
and a bootstrapping method applied to the fit results of the NLLS approach (f). The visual analysis of the
uncertainty maps reveals very similar patterns for both approaches, supported by a SSIM of 91%. The highest
uncertainty occurs in regions with the highest percentage error for the fitting parameter estimates. The
remaining parameter combinations have much greater precision. Information about divergences (BTM) and
pixels where the NLLS algorithm did not find a solution can be found in Table 3, together with computational
times for fitting all 3000 pixels with BTM and NLLS approaches and the additional bootstrap analysis.
Table 3: Fitting process and parameter estimation of all 50×60 DRO con-
centration curves
BTM NLLS
Divergences 17 27
Computational time: fitting ∼ 48 min ∼ 2 min
Computational time: uncertainty included ∼ 2100 min*
BTM = Bayesian Tofts Model; NLLS = Non-linear Least Squares approach
* Based on additional bootstrap analysis
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Figure 2: Estimated Ktrans with BTM (top) and NLLS approach (bottom). The left column displays median
(a) and point estimates (d). The middle column (b,e) shows the calculated percentage error between
estimates and ground truth. The right column illustrates the uncertainty σ of the Bayesian posterior (c)
and the additional bootstrap samples (f).
3.2 Application: Breast Cancer DCE-MRI Data
Fig. 3 shows representative signal intensity-time curves with the associated PPCs (a-c) and their corre-
sponding Ktrans posterior distributions (d). Here, the dark line illustrates the median and the increasingly
lighter bands are the 20%, 40%, 60% and 80% highest density intervals (HDI) between the corresponding
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(0.4,0.6), (0.3,0.7), (0.2,0.8) and (0.1,0.9) percentiles of the posterior predictive distribution. The PPC in
(a) indicates a good fit of the model to the data, the corresponding posterior distribution (green) for Ktrans
is narrow. The PPC in (b) suggests that the chosen model provides a good fit to the data, the high noise
level in the data is associated with a broader posterior distribution (orange). In (c), the noise level of the
data is comparable to (a), however the PPC indicates a modeling error.
Fig. 4 shows the posterior distributions of Ktrans for all patients for visit 1 (blue) and visit 2 (orange),
before and during NACT, respectively. With one exception, a general decrease in Ktrans is observed. The
degree of change, dependent on the width of the posterior distributions, is summarized in Cohen’s d values
and visualized in Fig. 5; light-gray represents non-pCR, dark-gray pCR. The ULR analysis revealed a ROC
AUC of 0.952. Computational time for fitting all 20 ROI-averaged concentration curves was ∼ 20 s for the
BTM.
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Figure 3: Observed signal intensity-time courses (dots) with posterior predictive distribution median (line)
and the 20%, 40%, 60% and 80% highest density intervals (HDI); (a) for a good fit to data with low noise
level, (b) for a good fit to data with high noise level, and (c) for a bad fit to data with low noise level. (d)
Posterior distributions for Ktrans estimated from the respective signal intensity-time curves (color-coded).
4 Discussion
In this study, we assessed posterior probability distributions of tracer-kinetic parameters obtained with a
BTM against a standard NLLS approach. Validation with a DRO revealed high accuracy of BTM and
NLLS approaches, indicated by strong similarity between estimated and ground truth maps. In addition,
precision of estimates, assessed via the width of the posterior probability distributions and bootstrapping,
respectively, was in very good agreement between both approaches. Analysis of the breast cancer DCE-MRI
dataset with the BTM revealed that the degree of decrease in Ktrans gives information about the pathologic
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Figure 4: Posterior probability densities of Ktrans for all patients. Blue corresponds to visit 1, orange to
visit 2. BC05, BC06 and BC15 are labeled pCR, the rest non-pCR.
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Figure 5: Cohen’s d calculated from Ktrans posterior distributions for all patients; sorted by value.
response to NACT. The response in dependence of the uncertainty of parameter estimates was quantified
with Cohen’s d, calculated from the posterior distributions between visit 1 and 2. ULR modeling indicated
excellent prediction of response.
Concerning the analysis of the DRO with the BTM, median parameter estimates were compared to the
ground truth to assess the accuracy, otherwise not available with measured data. It was found that the
Bayesian estimates generally have a very strong similarity with the ground truth, validating the accuracy
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of our BTM. The recovered parameters also have complementary regions of high and low percentage errors
compared to the established NLLS fitting routine. RMS errors were lower for both implementations in the
present work compared to similar DRO analysis by Smith et al. (2015) and Ortun˜o et al. (2013). Albeit,
the results are in good comparison. Caution is still required for voxels with low ve. Concentration curves
with these parameter combinations have very limited intensity changes which practically vanish in the added
background noise.
The variance of estimates inherent in the Bayesian posterior distribution was compared to a bootstrapping
error analysis, performed likewise to the work of Kershaw and Buckley (2006). It was demonstrated that the
uncertainty maps of the BTM resemble those calculated with the bootstrap analysis, validating the precision
of parameters recovered with the BTM. To the best of our knowledge, only Schmid et al. (2006) implemented
a Bayesian PK model with the objective to make use of the posterior probability distribution. They used it
to state the probability of a pixel to be greater than a certain threshold for tumor masking. Their approach
was applied to patient data, whereas in the present work, accuracy and precision of estimates were validated
with a digital phantom first.
Furthermore, we applied the BTM to the breast cancer DCE-MRI data, performed PPCs and investi-
gated the posterior distributions. For a PPC, the observed data was compared to the posterior predictive
distribution, illustrated as percentile intervals of highest density. A good fit to the data results in a posterior
distribution which reflects the noise level in the data; low noise corresponds to a narrow posterior and vice
versa. However, a bad fit to the data results in a broad posterior distribution despite a low noise level. This
indicates a systematic modeling error which influences the information we gained about uncertainty. More
complex PK models which incorporate additional assumptions about CA transport, e.g. the extended Tofts
model, could be able to produce a better fit to certain data. Hence, assessing posterior distributions requires
to check the corresponding data and fit before drawing any conclusions from it. While feasible for ROI-based
analysis with only a handful of concentration curves, visual assessment is not possible in a pixelwise analy-
sis. An automated Bayesian model selection step as proposed in the work of Duan et al. (2017) could be an
effective means to reduce systematic modeling error but is beyond the scope of this study.
In order to assess therapy response for the patients in the breast cancer DCE-MRI dataset, Huang et al.
(2014a) showed in their original work that using visit 2 Ktrans or the percentage change of Ktrans between
visits as metrics yields good to excellent results. However, the uncertainty in estimating PK parameters
with tracer-kinetic models is not accounted for. For this purpose, we calculated Cohen’s d as a means of
quantitative change in parameter estimates which depends on the precision of estimates. Using Cohen’s d
metric, the assessment of response was found to be excellent by means of an ULR analysis. Considering the
findings of the PPCs, including a model selection step as explained above could decrease the influence of
systematic modeling errors on posterior distributions and hence Cohen’s d values which may further improve
assessment of therapy response.
Limitations of the present work include large computational time when fitting the BTM to the DRO-data.
On the one hand, the MCMC sampling is time and memory consuming but necessary to avoid divergences.
On the other hand, it yields a full posterior probability distribution with information about the uncertainty,
and obtaining the same information with a bootstrap analysis of a NLLS fit requires even more computation
time. Furthermore, the simulated DRO curves have a much higher time-resolution compared to measured
data. Evaluating real DCE-MRI data increases the speed of the analysis greatly. Moreover, the influence of
the chosen prior distributions on the results was not assessed in the present study.
In conclusion, we evaluated a BTM with a DRO, assessed accuracy and precision against the standard
NLLS approach and showed how posterior distributions are used to assess therapy response. We demon-
strated that Bayesian modeling provides an elegant means to assess posterior probability distributions, which
are in good agreement with established approaches.
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A Prior Predictive Check
Figure A.1: Prior probability density functions for Ktrans (a), ve (b), σ (c) and the subsequent prior
predictive check (d). Simulated concentration-time curves (dots) for each parameter combination of the
QIBA phantom are overlaid on the prior predictive distribution; illustrated by median (line) and the 20% -
80% highest density intervals (HDI).
To assess if the choice of prior distributions for the model parameters covers a reasonable range of
concentration-time curves, it is useful to perform a prior predictive check. For this purpose, we generated
100,000 MCMC samples from the prior predictive distribution,
P (yˆ) =
∫
P (yˆ | θ)P (θ)dθ, (13)
only considering the prior distributions without any actual data. This quantifies the range of possible
observations yˆ, predicted by our model. In a prior predictive check, the predicted data is compared to
real observations and the extent of extreme observations indicates the level of disagreement between domain
expertise and model assumptions. Fig. A.1 shows the probability density functions of the chosen priors (a-c)
and the prior predictive check (d). The black dots are actual observed data from the QIBA phantom, one
curve for each parameter combination of Ktrans and ve, to assess the scope of possible phantom curves. The
increasingly lighter green bands represent the 20%, 40%, 60% and 80% highest density intervals between the
corresponding percentiles of the prior predictive distribution; the green line is the median thereof. We find
that the model predicts observations that are more extreme than the phantom data but not too extreme to
be unrealistic given the assumed observational error. Hence, we conclude that the chosen prior distributions
are reasonable.
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